These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 23602047

  • 1. Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website.
    Everitt H, Moss-Morris R, Sibelli A, Tapp L, Coleman N, Yardley L, Smith P, Little P.
    BMC Gastroenterol; 2013 Apr 21; 13():68. PubMed ID: 23602047
    [Abstract] [Full Text] [Related]

  • 2. Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial).
    Everitt HA, Moss-Morris RE, Sibelli A, Tapp L, Coleman NS, Yardley L, Smith PW, Little PS.
    BMC Gastroenterol; 2010 Nov 18; 10():136. PubMed ID: 21087463
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial.
    Kennedy TM, Chalder T, McCrone P, Darnley S, Knapp M, Jones RH, Wessely S.
    Health Technol Assess; 2006 Jun 18; 10(19):iii-iv, ix-x, 1-67. PubMed ID: 16729918
    [Abstract] [Full Text] [Related]

  • 5. Exploring patients' views of a cognitive behavioral therapy-based website for the self-management of irritable bowel syndrome symptoms.
    Tonkin-Crine S, Bishop FL, Ellis M, Moss-Morris R, Everitt H.
    J Med Internet Res; 2013 Sep 03; 15(9):e190. PubMed ID: 24001787
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care.
    Moss-Morris R, McAlpine L, Didsbury LP, Spence MJ.
    Psychol Med; 2010 Jan 03; 40(1):85-94. PubMed ID: 19531276
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome.
    Lackner JM, Jaccard J, Keefer L, Brenner DM, Firth RS, Gudleski GD, Hamilton FA, Katz LA, Krasner SS, Ma CX, Radziwon CD, Sitrin MD.
    Gastroenterology; 2018 Jul 03; 155(1):47-57. PubMed ID: 29702118
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ford AC, Wright-Hughes A, Alderson SL, Ow PL, Ridd MJ, Foy R, Bianco G, Bishop FL, Chaddock M, Cook H, Cooper D, Fernandez C, Guthrie EA, Hartley S, Herbert A, Howdon D, Muir DP, Nath T, Newman S, Smith T, Taylor CA, Teasdale EJ, Thornton R, Farrin AJ, Everitt HA, ATLANTIS trialists.
    Lancet; 2023 Nov 11; 402(10414):1773-1785. PubMed ID: 37858323
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility.
    Lackner JM, Jaccard J, Krasner SS, Katz LA, Gudleski GD, Holroyd K.
    Clin Gastroenterol Hepatol; 2008 Aug 11; 6(8):899-906. PubMed ID: 18524691
    [Abstract] [Full Text] [Related]

  • 19. Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up.
    Lackner JM, Jaccard J, Radziwon CD, Firth RS, Gudleski GD, Hamilton F, Katz LA, Keefer L, Krasner SS, Ma CX, Sitrin MD, Brenner DM.
    Am J Gastroenterol; 2019 Feb 11; 114(2):330-338. PubMed ID: 30429592
    [Abstract] [Full Text] [Related]

  • 20. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
    Johnsen PH, Hilpüsch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, Goll R.
    Lancet Gastroenterol Hepatol; 2018 Jan 11; 3(1):17-24. PubMed ID: 29100842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.